Stay updated on clinical development milestones and clinical trial approvals we are proud to help our sponsors achieve
OCT completed the interim analysis for the clinical study in the blepharoconjunctivitis diagnosed patients.
The results of the analysis confirmed OCT team’s assumptions on the sample size. The trial is to be completed on schedule.
This is a multicenter, double-blind, randomized, placebo-controlled phase III study. . The treatment period is 15 days. The planned recruitment target is 200 female and male patients over 18 years old.
Within this project, OCT is responsible for a scope of services including site selection, project management, data management, clinical and medical monitoring and final report preparation.
* - Required fields